Literature DB >> 8765523

Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.

K E Bergmann1, M H Cynamon, J T Welch.   

Abstract

Substituted pyrazinoic acid esters have previously been reported to have in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as Mycobacterium tuberculosis. Modification of both the pyrazine nucleus and the ester functionality was successful in expanding the antimycobacterial activity associated with pyrazinamide to include M. avium and M. kansasii, organisms usually not susceptible to pyrazinamide. In an attempt to understand the relationship between the activity of the esters with the needed biostability, a quantitative structure-activity relationship has been developed. This derived relationship is consistent with the observation that tert-butyl 5-chloropyrazinoate (13) and 2'-(2'-methyldecyl) 5-chloropyrazinoate (25), compounds which are both 100-fold more active than pyrazinamide against M. tuberculosis and possess a serum stability 900-1000 times greater than the lead compounds in the series.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765523     DOI: 10.1021/jm950538t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

2.  Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.

Authors:  David Pires; Emília Valente; Marta Filipa Simões; Nuno Carmo; Bernard Testa; Luís Constantino; Elsa Anes
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

3.  Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.

Authors:  Oren Zimhony; Catherine Vilchèze; Masayoshi Arai; John T Welch; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

4.  Ester-prodrugs of ethambutol control its antibacterial activity and provide rapid screening for mycobacterial hydrolase activity.

Authors:  Erik M Larsen; Dominique C Stephens; Nathan H Clarke; R Jeremy Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-08-30       Impact factor: 2.823

Review 5.  Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance.

Authors:  Erik M Larsen; R Jeremy Johnson
Journal:  Drug Dev Res       Date:  2018-10-10       Impact factor: 4.360

6.  Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis.

Authors:  João Paulo-Dos Santos Fernandes; Fernando Rogerio Pavan; Clarice Queico Fujimura Leite; Veni Maria Andres Felli
Journal:  Saudi Pharm J       Date:  2013-12-25       Impact factor: 4.330

7.  A Computational Study of Cytotoxicity of Substituted Amides of Pyrazine- 2-carboxylic acids Using QSAR and DFT Based Molecular Surface Electrostatic Potential.

Authors:  Sharieh Hosseini; Majid Monajjemi; Elahe Rajaeian; Mohammad Haghgu; Aliakbar Salari; Mohammad Reza Gholami
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

8.  Design, synthesis and evaluation of biological activities of some novel anti-TB agents with bio-reducible functional group.

Authors:  Hossein Khani-Meinagh; Hossein Mostafavi; Norbert Reiling; Majid Mahdavi; Gholamreza Zarrini
Journal:  Bioimpacts       Date:  2019-05-22

9.  N-Pyrazinoyl Substituted Amino Acids as Potential Antimycobacterial Agents-The Synthesis and Biological Evaluation of Enantiomers.

Authors:  Martin Juhás; Lucie Kučerová; Ondřej Horáček; Ondřej Janďourek; Vladimír Kubíček; Klára Konečná; Radim Kučera; Pavel Bárta; Jiří Janoušek; Pavla Paterová; Jiří Kuneš; Martin Doležal; Jan Zitko
Journal:  Molecules       Date:  2020-03-27       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.